Second, the persuit of cancer-related clinical trials for BET inhibitors [23–25, 35] suggests that Brd2 haploinsufficiency reduces cancer incidence in humans, just as our HET mice showed markedly reduced cancer incidence compared to WT (Table 3). This evidence concerns the gene BRD2 and cancer.